FindTrial
Sign In

IMiD treatment

DRUG3 trials

Sponsors

Bristol-Myers Squibb, Sung-Soo Park

Conditions

Burkitt LymphomaDiffuse Large B Cell Lymphoma RelapsedHigh Grade B-cell LymphomaMultiple MyelomaMultiple Myeloma (MM)Multiple Myeloma, RelapsedPrimary Mediastinal Large B-Cell LymphomaRelapsed/refractory High Grade B Cell Lymphoma

Unknown Phase

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
CompletedNCT06160167
Bristol-Myers SquibbMultiple Myeloma
Start: 2023-10-01End: 2024-08-01Updated: 2024-08-23
Immunotherapy in Lymphoma
RecruitingNCT06796517
Sung-Soo ParkBurkitt Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, High Grade B-cell Lymphoma +2
Start: 2024-06-26End: 2025-12-31Target: 72Updated: 2025-01-28
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
RecruitingNCT07051850
Sung-Soo ParkMultiple Myeloma (MM), Multiple Myeloma, Relapsed
Start: 2025-07-14End: 2025-12-31Target: 174Updated: 2025-07-15